Omega-3 API maker KD Pharma snaps up U.K. manufacturing site for undisclosed price

Pills and vitamins
The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. (Steven Depolo/CC BY 2.0)

KD Pharma, a Swiss API maker of omega-3 products, has snapped up a manufacturing site in Seal Sands, U.K., for an undisclosed price.

The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. The Seal Sands facility was previously used to make omega-3 products.

KD Pharma, which employs about 400 people globally, has seven sites situated in the U.K. and U.S. The company makes omega-3 fatty acid products that are used in finished products like soft gel capsules and bottled liquid forms of pharmaceutical products.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“The acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” Oscar Groet, KD Pharma’s chief executive, said in a statement. “The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids.”

The Seal Sands plant is expected to be up and running for KD Pharma by the end of the year. The company’s other sites include Bexbach, Germany, Brattvagm, Norway and Miami.

Read more on

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.